[go: up one dir, main page]

AR119884A1 - Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación - Google Patents

Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación

Info

Publication number
AR119884A1
AR119884A1 ARP200102458A ARP200102458A AR119884A1 AR 119884 A1 AR119884 A1 AR 119884A1 AR P200102458 A ARP200102458 A AR P200102458A AR P200102458 A ARP200102458 A AR P200102458A AR 119884 A1 AR119884 A1 AR 119884A1
Authority
AR
Argentina
Prior art keywords
saccharide
carrier protein
antigen
protein conjugate
enterica serovar
Prior art date
Application number
ARP200102458A
Other languages
English (en)
Inventor
Rajeev Halasakant Dhere
Sambhaji Shankar Pisal
Dattatreya Sarma Annamraju
Nikhil Dattatray Avalaskar
Yogesh Tukaram Hundekari
Anil Pirajirao Taklikar
Sunil Kumar Goel
Chandrashekhar Dwarkanath Kamat
Vishal Bharat Chavan
Original Assignee
Serum Inst Of India Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst Of India Private Ltd filed Critical Serum Inst Of India Private Ltd
Publication of AR119884A1 publication Critical patent/AR119884A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a composiciones de vacuna conjugadas de polisacárido-proteína inmunogénicas monovalentes y multivalentes que comprenden un polisacárido seleccionado de las cepas serovar de Salmonella S. typhi, S. paratyphi A, S. typhimurium y S. enteritidis y métodos alternativos mejorados de fermentación de polisacáridos, purificación de polisacáridos, conjugación de polisacárido-proteína y formulación estable. La presente divulgación se refiere además a métodos para inducir una respuesta inmune en sujetos contra enfermedades relacionadas con Salmonella typhi y/o para reducir o prevenir enfermedades relacionadas con Salmonella typhi y no typhi en sujetos que usan las composiciones descritas en este documento. La vacuna entrega anticuerpos bactericidas y es útil para la prevención de gastroenteritis, fiebre entérica y tifoidea. Reivindicación 1: Una composición inmunogénica que comprende: i) al menos un antígeno seleccionado de: a) conjugado de sacárido-proteína portadora de Salmonella enterica serovar typhi, b) conjugado de sacárido-proteína portadora de Salmonella enterica serovar paratyphi A, c) conjugado de sacárido-proteína portadora de Salmonella enterica serovar paratyphi B, d) conjugado de sacárido-proteína portadora de Salmonella enterica serovar paratyphi C, e) conjugado de sacárido-proteína portadora de Salmonella enterica serovar typhimurium, f) conjugado de sacárido-proteína portadora de Salmonella enterica serovar enteritidis, g) conjugado de sacárido-proteína portadora de Salmonella enterica serovar choleraesuis, h) conjugado de sacárido-proteína portadora de Salmonella enterica serovar dublin y ii) opcionalmente un antígeno seleccionado del grupo que comprende Salmonella (no tifoidea), toxoide de difteria (D), toxoide tetánico (T), tos ferina de células completas (wP), antígeno de superficie del virus de la hepatitis B (HBsAg), conjugado de proteína portadora-PRP de Haemophilus influenzae b (Hib), Haemophilus influenzae (serotipos a, c, d, e, f y las cepas no encapsuladas), virus de la polio, conjugado que comprende antígenos de N. meningitidis (A, B, C, D, W135, X, Y, Z y 29E), antígeno/s de Streptococcus pneumoniae (1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 6E, 6G, 6H, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9F, 9N, 9V, 10F, 10B, 10C, 10A, 11A, 11F, 11B, 11C, 11D, 11E, 12A, 12B, 12F, 13, 14, 15A, 15C, 15B, 15F, 16A, 16F, 17A, 17F, 18C, 18F, 18A, 18B, 19A, 19B, 19C, 19F, 20, 20A, 20B, 21, 22A, 22F, 23A, 23B, 23F, 24A, 24B, 24F, 25F, 25A, 27, 28F, 28A, 29, 31, 32F, 32A, 33A, 33C, 33D, 33E, 33F, 33B, 34, 45, 38, 35A, 35B, 35C, 35F, 36, 37, 38, 39, 40, 41F, 41A, 42, 43, 44, 45, 46, 47F, 47A, 48), Streptococcus spp Grupo A, Streptococcus Grupo B (grupo Ia, Ib, II, III, IV, V, VI, VII, VIII y IX), ampolla o antígeno/s de Neisseria meningitidis B (fHbp, PorA, fHbp-PorA quimérico), antígeno/s de Staphylococcus aureus, ántrax, BCG, antígeno/s de hepatitis (cepas A, C, D, E, F y G), virus del papiloma humano, VIH, tos ferina acelular, adenilato ciclasa modificada, antígeno de malaria (RTS, S), sarampión, paperas, rubéola, dengue, zika, ébola, chikungunya, encefalitis japonesa, Rotavirus, antígenos diarreicos (E. coli spp, Shigella spp, Campylobacter spp, Vibrio cholera), flavivirus, viruela, fiebre amarilla, culebrilla, antígenos de virus de la varicela.
ARP200102458A 2019-09-03 2020-09-03 Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación AR119884A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201921035435 2019-09-03

Publications (1)

Publication Number Publication Date
AR119884A1 true AR119884A1 (es) 2022-01-19

Family

ID=72659843

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102458A AR119884A1 (es) 2019-09-03 2020-09-03 Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación

Country Status (22)

Country Link
US (2) US20230149524A1 (es)
EP (2) EP4025246A2 (es)
JP (2) JP7732974B2 (es)
KR (2) KR20220087437A (es)
CN (1) CN114728053A (es)
AR (1) AR119884A1 (es)
AU (1) AU2020343943A1 (es)
BR (1) BR112022003892A2 (es)
CA (1) CA3149972A1 (es)
CO (1) CO2022003789A2 (es)
CR (1) CR20220132A (es)
EC (1) ECSP22031077A (es)
GB (2) GB2629746B (es)
GE (2) GEAP202515919A (es)
IL (1) IL291006B1 (es)
JO (1) JOP20200214A1 (es)
MA (1) MA56283A1 (es)
MX (1) MX2022002693A (es)
PE (1) PE20221442A1 (es)
PH (1) PH12022550525A1 (es)
WO (1) WO2021044436A2 (es)
ZA (1) ZA202203368B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025021712A1 (en) * 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
AU1420897A (en) * 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
RU2518289C2 (ru) 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
FR2938265B1 (fr) 2008-11-12 2011-07-15 Univ Claude Bernard Lyon Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble
KR101605171B1 (ko) * 2009-12-17 2016-03-21 피나 바이오솔루션스, 엘엘씨 접합 백신 제조시 다당류를 활성화시키기 위한 화학 시약
US9011871B2 (en) * 2011-11-07 2015-04-21 University Of Maryland, Baltimore Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease
IN2012MU00206A (es) * 2012-01-20 2013-08-09
MX354103B (es) 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
CN102935226B (zh) * 2012-11-16 2014-01-22 罗益（无锡）生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
EP3329935B1 (en) * 2013-08-24 2025-01-08 Bharat Biotech International Limited A bacterial vaccine and methods for manufacture thereof
CN104383532A (zh) * 2014-12-02 2015-03-04 云南沃森生物技术股份有限公司 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法
CN104587461A (zh) * 2015-01-05 2015-05-06 云南沃森生物技术股份有限公司 伤寒、甲型乙型副伤寒多糖蛋白结合型多价联合疫苗
WO2017006349A1 (en) * 2015-07-04 2017-01-12 Bharat Biotech International Limited Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
WO2017187448A1 (en) * 2016-04-25 2017-11-02 National Institute Of Immunology A novel conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate
PH12019500404B1 (en) 2016-08-26 2024-05-15 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
MY202666A (en) * 2017-05-05 2024-05-14 Serum Institute Of India Pvt Ltd Method for removal of impurities from bacterial capsular polysaccharide based preparations
CA3070039A1 (en) 2017-07-18 2019-01-24 Serum Institute Of India Pvt Ltd. An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
MX2021005500A (es) * 2018-11-10 2021-09-08 Bharat Biotech Int Ltd Composiciones inmunogenicas de glicoconjugados multivalentes.

Also Published As

Publication number Publication date
CN114728053A (zh) 2022-07-08
KR20220087437A (ko) 2022-06-24
GB2603362A (en) 2022-08-03
EP4249061A2 (en) 2023-09-27
US20250134980A1 (en) 2025-05-01
JP7732974B2 (ja) 2025-09-02
IL291006A (en) 2022-05-01
MX2022002693A (es) 2022-07-12
EP4025246A2 (en) 2022-07-13
JP2022546763A (ja) 2022-11-08
GEAP202515919A (en) 2025-05-27
AU2020343943A1 (en) 2022-03-24
WO2021044436A3 (en) 2021-05-27
BR112022003892A2 (pt) 2022-05-24
CO2022003789A2 (es) 2022-04-19
IL291006B1 (en) 2025-11-01
EP4249061A3 (en) 2023-11-15
MA56283A1 (fr) 2023-01-31
US20230149524A1 (en) 2023-05-18
CA3149972A1 (en) 2021-03-11
JOP20200214A1 (ar) 2021-03-03
KR20240155975A (ko) 2024-10-29
ZA202203368B (en) 2022-05-25
CR20220132A (es) 2022-05-06
GB2603362B (en) 2025-01-15
GB2629746B (en) 2025-01-29
GEP20257808B (en) 2025-10-27
JP2024178271A (ja) 2024-12-24
GB202204276D0 (en) 2022-05-11
PE20221442A1 (es) 2022-09-21
ECSP22031077A (es) 2022-05-31
PH12022550525A1 (en) 2023-03-20
GB2629746A (en) 2024-11-06
WO2021044436A2 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
JP7033175B2 (ja) 肺炎球菌ワクチンにおいて用いるための免疫原性組成物
US20260027195A1 (en) Immunogenic compositions for use in pneumococcal vaccines
JP2025122002A (ja) コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
DK2351578T3 (en) Method of Preparing Vaccines
US20190000952A1 (en) Immunogenic compositions for use in pneumococcal vaccines
HRP20160685T1 (hr) Pripravci koji sadrže pneumokokne antigene
JP2004501873A5 (es)
JP2005508849A5 (es)
JP2014218516A5 (es)
ES2240432T3 (es) Conjugados polisacaridos de neumococo para uso vacuna contra el tetanos y la difteria.
RU2006142156A (ru) Объединенные менингококковые конъюгаты с общим белком-носителем
Bartlett et al. Vaccine immunology
Baliban et al. Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS: FliC glycoconjugates in infant and adult mice
AR119884A1 (es) Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación
JP2012506420A (ja) 全細胞百日咳を含む混合ワクチン
ES2367918T5 (es) Procedimiento de fabricación de vacunas
US12533418B2 (en) Dosage and administration of a bacterial saccharide glycoconjugate vaccine
RU2827429C1 (ru) Иммуногенные композиции для применения в пневмококковых вакцинах
Segal et al. The future of meningitis vaccines
Moingeon Challenges and Opportunities in the Development of New Conjugate Vaccines against Infectious Diseases